Oncology
1 drug is in development for Lung Neoplasms.
- Companies
- 1
- Clinical trials
- 16
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Lung Neoplasms pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Taletrectinib | Nuvation Bio Inc. (NUVB) |
About this indication
Lung Neoplasms context
Oncology·MeSH: Lung Neoplasms (D008175)
Also known as: Lung Neoplasm, Neoplasm, Pulmonary, Neoplasms, Pulmonary
Narrower concepts tracked separately: Lung Cancer, Lung Cancer (NSCLC), Lung Cancer (Diagnosis)
Prevalence
3358.2 / 100K
Incidence
1547.2 / 100K/yr
Frequently asked questions
How many drugs are in development for Lung Neoplasms?
BioSniper tracks 1 drug in development for Lung Neoplasms across 1 company.
How many clinical trials target Lung Neoplasms?
There are 16 clinical trials targeting Lung Neoplasms tracked by BioSniper.
What is the prevalence of Lung Neoplasms?
The estimated prevalence of Lung Neoplasms is approximately 3358.2 per 100,000 population.